Evexta Bio
Created in 2014
Up & running (A)
Existing signals show a regular activitySocial networks
343 1,950 1,950Activities
Technologies
Entity types
Location
104 Bd de Sébastopol, 75003 Paris, France
Paris
France
Employees
Scale: 2-10
Estimated: 12
Engaged catalyst
6
0 0Added in Motherbase
3 years, 2 months ago
Value proposition
Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:
- Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer.
- EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in hematological and solid tumors.
Founded by Truffle Capital, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA (Darmstadt, Germany). The company is supported by seasoned management team, board of directors and medical advisory board.
Pharmaceuticals, Research & Development, oncology, biotech, KIF20A inhibitor, TRUFFLE CAPITAL, Rupitasertib, S6K AKT1/3 inhibitor, and DiaccurateOriginal language
Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:
- Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer.
- EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in hematological and solid tumors.
Founded by Truffle Capital, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA (Darmstadt, Germany). The company is supported by seasoned management team, board of directors and medical advisory board.
Homepage | Evextabio
https://www.evextabio.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Biotechnology Innovation Organization | Other 26 May 2024 | | |
 Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Other 30 Jun 2022 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 5 Jan 2023 | | |
 Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Other 13 Sep 2021 | | |
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Not capitalistic Not partnership Event 22 Nov 2021 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Not capitalistic Partnership Event 8 Aug 2019 | | |